Loading company…
Swedish biopharmaceutical firm developing central nervous system therapies, led by UMC-119 for hepatic encephalopathy.
Founded in 2006 and headquartered in Sweden, Umecrine AB develops therapies for central nervous system disorders. Its lead product, UMC-119, targets hepatic encephalopathy. The company's most recent deal was a VENTURE DEBT round on December 19, 2024, raising SEK 23.8 million from investors including Karolinska Development and Ribbskottet AB. It has completed three funding deals in total.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in